Mark Brandt

5.2k total citations
89 papers, 2.9k citations indexed

About

Mark Brandt is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mark Brandt has authored 89 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Hematology, 30 papers in Molecular Biology and 28 papers in Genetics. Recurrent topics in Mark Brandt's work include Acute Myeloid Leukemia Research (68 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Acute Lymphoblastic Leukemia research (21 papers). Mark Brandt is often cited by papers focused on Acute Myeloid Leukemia Research (68 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Acute Lymphoblastic Leukemia research (21 papers). Mark Brandt collaborates with scholars based in United States, Netherlands and Canada. Mark Brandt's co-authors include Hagop M. Kantarjian, Guillermo Garcia‐Manero, Jörge E. Cortes, Farhad Ravandi, Sherry Pierce, Gautam Borthakur, Stefan Faderl, Susan O’Brien, Tapan M. Kadia and Michael J. Keating and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mark Brandt

85 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Brandt United States	28	2.0k	1.0k	850	763	616	89	2.9k
Maria Christina Cox Italy	30	1.2k 0.6×	850 0.8×	516 0.6×	498 0.7×	842 1.4×	111	2.8k
G Harrison United Kingdom	19	4.0k 2.0×	1.7k 1.6×	1.0k 1.2×	1.9k 2.5×	543 0.9×	30	4.6k
Elisabetta Abruzzese Italy	27	2.5k 1.3×	399 0.4×	1.8k 2.1×	456 0.6×	538 0.9×	150	3.2k
W. Hiddemann Germany	25	758 0.4×	731 0.7×	387 0.5×	298 0.4×	633 1.0×	100	2.0k
Fred G. Behm United States	23	1.1k 0.5×	675 0.7×	270 0.3×	1.3k 1.7×	399 0.6×	38	2.3k
Alistair Reid United Kingdom	25	2.8k 1.4×	389 0.4×	2.4k 2.9×	378 0.5×	386 0.6×	70	3.6k
Akil Merchant United States	24	818 0.4×	1.5k 1.4×	226 0.3×	385 0.5×	836 1.4×	84	2.5k
David T Yeung Australia	22	1.6k 0.8×	408 0.4×	1.3k 1.5×	356 0.5×	358 0.6×	131	2.3k
Kendra Sweet United States	22	1.1k 0.6×	617 0.6×	604 0.7×	170 0.2×	647 1.1×	180	1.8k
Katy Rezvani United States	24	1.4k 0.7×	309 0.3×	783 0.9×	296 0.4×	641 1.0×	71	2.6k

Countries citing papers authored by Mark Brandt

Since Specialization

Citations

This map shows the geographic impact of Mark Brandt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Brandt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Brandt more than expected).

Fields of papers citing papers by Mark Brandt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Brandt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Brandt. The network helps show where Mark Brandt may publish in the future.

Co-authorship network of co-authors of Mark Brandt

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Brandt. A scholar is included among the top collaborators of Mark Brandt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Brandt. Mark Brandt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borthakur, Gautam, Farhad Ravandi, Keyur P. Patel, et al.. (2022). Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. American Journal of Hematology. 97(11). 1427–1434. 20 indexed citations

Kim, Kunhwa, Marina Konopleva, Courtney D. DiNardo, et al.. (2022). Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology. 97(7). 885–894. 6 indexed citations

Borthakur, Gautam, Jörge E. Cortes, Farhad Ravandi, et al.. (2019). Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). Blood. 134(Supplement_1). 290–290. 21 indexed citations

Boddu, Prajwal, Jörge E. Cortes, Farhad Ravandi, et al.. (2017). Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood. 130. 27–27. 1 indexed citations

Assi, Rita, Prithviraj Bose, Srđan Verstovšek, et al.. (2017). The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood. 130. 1379–1379. 2 indexed citations

Pemmaraju, Naveen, Hagop M. Kantarjian, Joseph D. Khoury, et al.. (2017). Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 130. 3855–3855. 5 indexed citations

Oran, Betül, Jörge E. Cortes, Amer Beitinjaneh, et al.. (2016). Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22(7). 1218–1226. 59 indexed citations

Pierce, Sherry, Mark Brandt, Srđan Verstovšek, et al.. (2015). Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). Blood. 126(23). 1587–1587. 4 indexed citations

Christopherson, Cody D., Bradford J. Wiggins, Nicole Legate, et al.. (2013). Collaborative Replications and Education Project (CREP). OSF Preprints (OSF Preprints). 21 indexed citations

10.

Ghanem, Hady, A. Megan Cornelison, Guillermo Garcia‐Manero, et al.. (2013). Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clinical Lymphoma Myeloma & Leukemia. 13. S289–S294. 2 indexed citations

11.

Jabbour, Elias, Guillermo Garcia‐Manero, Jörge E. Cortes, et al.. (2012). Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 12(4). 244–251. 27 indexed citations

12.

Ravandi, Farhad, Keyur P. Patel, Rajyalakshmi Luthra, et al.. (2011). Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin. Cancer. 118(10). 2665–2673. 38 indexed citations

13.

Al‐Kali, Aref, Jörge E. Cortes, Stefan Faderl, et al.. (2011). Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 11(4). 361–366. 21 indexed citations

14.

Konoplev, Sergej, E. Lin, S. Faderl, et al.. (2011). Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica. 97(2). 235–240. 10 indexed citations

15.

Gardner, Alison, Gloria Mattiuzzi, Stefan Faderl, et al.. (2008). Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. Journal of Clinical Oncology. 26(35). 5684–5688. 84 indexed citations

16.

Thomas, Deborah A., Stefan Faderl, Susan O’Brien, et al.. (2006). Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia. Cancer. 106(7). 1569–1580. 369 indexed citations

17.

Razzouk, Bassem I., Elihu H. Estey, Stanley Pounds, et al.. (2006). Impact of age on outcome of pediatric acute myeloid leukemia. Cancer. 106(11). 2495–2502. 42 indexed citations

18.

Canalli, Andréia A., Hui Yang, Sima Jeha, et al.. (2005). Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leukemia Research. 29(8). 881–885. 14 indexed citations

19.

Okcu, M. Fatih, W. Mark Roberts, Dennis A. Johnston, et al.. (2003). Risk classification at the time of diagnosis differentially affects the level of residual disease in children with B-precursor acute lymphoblastic leukemia after completion of therapy. Leukemia Research. 27(8). 743–750.

20.

Bunin, Nancy, Dennis A. Johnston, W. Mark Roberts, et al.. (2003). Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features. British Journal of Haematology. 120(4). 711–715. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact